These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical study on acute kidney injury after myeloablative allogeneic hematopoietic cell transplantation].
    Author: Bao YS, Jiang EL, Wang M, Huang Y, Wei JL, Yang DL, Feng SZ, Han MZ.
    Journal: Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):401-4. PubMed ID: 19031744.
    Abstract:
    OBJECTIVE: To explore the incidence, pathogenesis, risk factors, prophylaxis and treatment of acute kidney injury (AKI) after myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: Clinical data of 120 patients received myeloablative allo-HSCT were retrospectively analyzed. RESULTS: Serum creatinine level in the patients showed significantly higher than baseline value at 28-60 days after transplantation (P<0.05). 73 patients (60.8%) developed AKI at a median of 33 days after allo-HSCT, including grade 2 in 32 patients (26.7%). Patients with grade 1 AKI showed significant higher serum cyclosporine A (CsA) levels (P<0.05). Hepatic veno-occlusive disease( HVOD), acute graft-versus-host disease (aGVHD) and total bilirubin > 40 micromol/L were high risk factors of occurring AKI (P<0.05). 19 patients died within 100 days after allo-HSCT, grade 2 AKI was a high risk factor of mortality (P< 0.05). 180-day survival rate was significantly lower in patients with grade 2 AKI after allo-HSCT (P<0.05). CONCLUSION: AKI is one of the major complications after myeloablative allo-HSCT. Prophylaxis and treatment of AKI might reduce mortality in early stage of transplantation.
    [Abstract] [Full Text] [Related] [New Search]